| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 1998;29:2245-2253.)
© 1998 American Heart Association, Inc.
Original Contributions |
Cerebrovascular Ischemic Events With High Positive Anticardiolipin Antibodies
From the Center for Stroke Research, Department of Neurology, Henry Ford Health Science Center (Detroit Campus of Case Western University), Detroit, Mich.
Correspondence to Steven R. Levine, MD, DMC/WSU Stroke Program, Department of Neurology, WSU School of Medicine, University Health Center 6E, 4201 St Antoine, Detroit, MI 48201-2153. E-mail slevine{at}med.wayne.edu
Background and Purpose—The aim of our study was to characterize the patient profile and prognostic value associated with high positive IgG (>100 GPL) anticardiolipin antibodies (aCL).
Methods—We studied the clinical, laboratory, radiological, and prospective historical features of ischemic cerebrovascular disease in patients with >100 GPL titers. From our neurology department, 27 consecutive patients were prospectively identified and followed up (mean follow-up time, 34 months).
Results—The mean age of our cohort was 41 years. Lupuslike illness occurred in 3; 23 had primary antiphospholipid syndrome, including 3 who met criteria for Sneddon's syndrome; 1 patient had progressive systemic sclerosis. Cerebral infarcts occurred in 74% and were recurrent in 37%. Systemic ischemic events, most commonly deep vein thrombosis, occurred in 37%. Tobacco use was documented in 85%, hyperlipidemia in 74%, hypertension in 44%, and diabetes mellitus in 7% of patients. A prominent headache history was present in 67%. Lupus anticoagulant (LA) was present in 72%, approximately one half had positive antinuclear antibodies and thrombocytopenia, and one quarter had a false-positive VDRL. We compared mean GPL levels in patients testing positive for specific laboratory features of antiphospholipid syndrome with those testing negative for these parameters. Only the LA(+) group had a significantly higher mean GPL than the LA(-) group (P=0.006). Brain imaging showed nonlacunar infarcts in 73% and lacunes in 12%. Of 19 cerebral angiograms, 5 (26%) showed large-vessel occlusive disease and 6 (32%) branch obstruction. Echocardiograms were abnormal in 75%: thickened left-sided valves in 33% and vegetations in 12%. Recurrent cerebrovascular ischemic events were observed in 96%, with transient events (mean rate, 25%/y) occurring 5 times more frequently than strokes (mean rate, 5%/y). Using a standardized disability scale blinded to aCL titer, neurological impairment was severe in 7%, moderate in 30%, and mild or nonexistent in 63%, and unrelated to mean GPL value (P=0.567). Titers fluctuated greatly for individual patients, and most did not consistently test as highly positive. An analysis of fluctuation in symptom severity with concurrent GPL values did not show a statistically significant correlation. Compared with historical controls having a wide range of positive titers, the presence of high IgG aCL titers did not confer a worse prognosis for disability and recurrent ischemic events.
Conclusions—Our data suggest that cerebrovascular events associated with high positive GPL are frequently multiple and minor (with no disability-titer correlation), present in relatively young patients, and often associated with tobacco abuse, hyperlipidemia, LA, systemic ischemic events, and occult cardiac disease.
Key Words: antibodies, anticardiolipin • antibodies, antiphospholipid • anticoagulants, lupus • antiphospholipid syndrome • cerebral ischemia, transient • cerebrovascular disorders • stroke • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  A.W.S. de Souza, N.P. Silva, J.F. de Carvalho, V. D'Almeida, M.A.E. Noguti, and E.I. Sato Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome Lupus, October 1, 2007; 16(10): 782 - 787. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Sofat, O. Malik, and C.S. Higgens Neurological involvement in patients with rheumatic disease QJM, February 1, 2006; 99(2): 69 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L J Jara, G Medina, O Vera-Lastra, and L Barile The impact of gender on clinical manifestations of primary antiphospholipid syndrome Lupus, August 1, 2005; 14(8): 607 - 612. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Ruiz-Irastorza and M. A. Khamashta Stroke and antiphospholipid syndrome: the treatment debate Rheumatology, August 1, 2005; 44(8): 971 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lanthier, F. J. Kirkham, L. G. Mitchell, R. M. Laxer, E. Atenafu, C. Male, M. Prengler, T. Domi, A. K.C. Chan, R. Liesner, et al. Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children Neurology, January 27, 2004; 62(2): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Katzav, J Chapman, and Y Shoenfeld CNS dysfunction in the antiphospholipid syndrome Lupus, December 1, 2003; 12(12): 903 - 907. [Abstract] [PDF]
|
|
|
|
|
|
S Morelli, M L Bernardo, F Viganego, A Sgreccia, P De Marzio, F Conti, R Priori, and G Valesini Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus Lupus, November 1, 2003; 12(11): 805 - 812. [Abstract] [PDF]
|
|
|
|
|
|
R L Brey, J Chapman, S R Levine, G Ruiz-Irastorza, R H. Derksen, M Khamashta, and Y Shoenfeld Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 Lupus, July 1, 2003; 12(7): 508 - 513. [Abstract] [PDF]
|
|
|
|
|
|
D. Erkan, Y. Yazici, M. G. Peterson, L. Sammaritano, and M. D. Lockshin A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome Rheumatology, August 1, 2002; 41(8): 924 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C Keswani and N. Chauhan Antiphospholipid syndrome J R Soc Med, January 7, 2002; 95(7): 336 - 342. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ahmed, B. Stegmayr, J. Trifunovic, L. Weinehall, G. Hallmans, and A. K. Lefvert Anticardiolipin Antibodies Are Not an Independent Risk Factor for Stroke : An Incident Case-Referent Study Nested Within the MONICA and Vasterbotten Cohort Project Stroke, June 1, 2000; 31(6): 1289 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Kirkham, M. Prengler, D. K.M. Hewes, and V. Ganesan Risk Factors for Arterial Ischemic Stroke in Children J Child Neurol, May 1, 2000; 15(5): 299 - 307. [Abstract] [PDF]
|
|